

**ATTACHMENT TO
AMENDMENT AND RESPONSE TO OFFICE ACTION DATED MARCH 25, 2004**

GROUP I: Primary Human Breast Cancers

- (1) Iype LE, Michael M, Verma M & Iype PT (1998) *Development and characterization of new immortalized human breast cancer cell lines*. Cytotechnology 26:207-218.
- (2) Medina D & Oborn CJ (Nov. 1980) *Growth of preneoplastic mammary epithelial cells in serum-free medium*. Cancer Res 40(II)3982-3987. (abstract)
- (3) Peterson OW, van Deurs B, Nielsen KV, Madsen MW, Laursen I, Balslev I & Briand P (Feb. 1990) *Differential tumorigenicity of two autologous human breast carcinoma cell lines, HMT-3909S1 and HMT-3909S8, established in serum-free medium*. Cancer Res 50(4)1257-1270. (abstract)
- (4) Biran S, Vlodavsky I, Fuks Z, Lijovetzky G, Horowitz AT (Sep. 1986) *Growth of human carcinoma cells from biopsy specimens in serum-free medium on extracellular matrix*. Int J Cancer 38(3):345-354. (abstract)

GROUP II: Primary Human Prostate Cancers

- (1) Yasunaga Y, Nakamura K, Ewing CM, Isaacs WB, Hukku B & Rhim JS (Aug. 15, 2001) *A Novel Cell Culture Model for the Study of Familial Prostate Cancer*. Cancer Res 61, 5969-5973
- (2) Xu Y, Iyengar S, Roberts RL, Shappell SB & Peehl DM (2003) *Primary Culture Model of Peroxisome Proliferator-Activated Receptor γ Activity in Prostate Cancer Cells*. J Cell Physiol 196:131-143.
- (3) Krill D, Shuman M, Thompson MT, Becich MJ & Strom SC (1997) *A Simple Method for the Isolation and Culture of Epithelial and Stromal Cells From Benign and Neoplastic Prostates*. Urology 49:981-988.
- (4) Chopra DP, Sakar FH, Grignon DJ, Sakr WA, Mohamed A, Waghray A (Sep. 1997) *Growth of human nondiploid primary prostate tumor epithelial cells in vitro*. Cancer Res 57(17)3688-3692. (abstract)
- (5) Chopra DP, Grignon DJ, Joiakim A, Mathieu PA, Mohamed A, Sakr WA, Powell IJ & Sakar FH (Nov. 1996) *Differential growth factor responses of epithelial cell cultures derived from normal human prostate, benign prostatic hyperplasia and primary prostate carcinoma*. J Cell Physiol 169(2)269-80. (abstract)
- (6) Peehl DM & Stamey TA (Feb. 1986) *Serum-free growth of adult human prostatic epithelial cells*. In Vitro Cell Dev Biol 22(2)82-90. (abstract)
- (7) Wang J, Torbenson M, Wang Q, Ro JY & Becich M (2003) *Expression of inducible nitric oxide synthase in paired neoplastic and non-neoplastic primary prostate cell cultures and prostatectomy specimen*. Urologic Oncology: Seminars and Original Investigations. 21:117-122.

GROUP III: Primary Human Pituitary Adenomas

- (1) Thodou E, Ramyar L, Cohen AI, Singer W & Asa SL (Winter 1995) *A Serum-Free System for Primary Cultures of Human Pituitary Adenomas*. Endocr Pathol 6(4)289-299. (abstract)

GROUP IV: Primary Human Endometrial Cancer

- (1) Reynolds RK, Owens CA & Roberts JA (1996) *Cultured endometrial cancer cells exhibit autocrine growth factor stimulation that is not observed in culture normal endometrial cells.* Gynecologic Oncology 60, 380-386, Article No. 0058.

GROUP V: Primary Human Lung Cancer

- (1) Miyazaki K, Masui H & Sato GH (1984) *Growth and Differentiation of Human Bronchogenic Epidermoid Carcinoma Cells in Serum-Free Media.* Methods for Serum Free Culture of Epithelial and Fibroblastic Cells, Vol 3, pp 83-94, Alan R Liss, New York.
- (2) Carney DN, Brower M, Bertness V & Oie HK (1984) *Selective Growth of Human Small Cell Lung Cancer Cell Lines and Clinical Specimens in Serum-Free Medium.* Methods for Serum Free Culture of Epithelial and Fibroblastic Cells, Vol 3, pp 57-71, Alan R Liss, New York.
- (3) Masuda N, Fukuoka M, Takada M, Kudoh S & Kusunoki Y (Aug. 1991) *Establishment and characterization of 20 human non-small cell lung cancer cell lines in serum-free defined medium (ACL-4).* Chest 100:429-438. (abstract)

GROUP VI: Primary Human Colon Cancer

- (1) van der Bosch J (1984) *Primary Tissue Cultures of Human Colon Carcinomas in Serum-Free Medium: An in Vitro System for Tumor Analysis and Therapy Experiments.* Methods for Serum Free Culture of Epithelial and Fibroblastic Cells, Vol 3, pp 73-81, Alan R Liss, New York.

GROUP VII: Primary Human Ovarian Cancer

- (1) Peretz T, Antebi SU, Beller U, Horowitz AT, Fuks Z & Vlodavsky I (Jun 1990) *Maintenance on extracellular matrix and expression of heparinase activity by human ovarian carcinoma cells from biopsy specimens.* Int J Cancer 45(6)1054-1060. (abstract)
- (2) Golombick T, Dansey R, Bezwoda WR & Rosendorff J (May 1990) *Establishment and characterization of two new human ovarian cancer cell lines UWOV1 and UWOV2 and a subline UWOV2 (Sf) growing in serum-free conditions: growth characteristics, biochemical, and cytogenetic studies.* In Vitro Cell Dev Biol 26(5)447-454. (abstract)
- (3) Hirte HW, Kaiser JS & Bacchetti S (Aug. 1994) *Establishment and characterization of four human epithelial ovarian carcinoma cell lines.* Cancer 74(3)900-906. (abstract)
- (4) Emoto M, Oshima K, Ishiguro M, Iwasaki H, Hawarabayashi T & Kikuchi M (1999) *Establishment and characterization of a serous papillary adenocarcinoma cell line of the human ovary in a serum-free culture.* Pathol Res Pract 195(4)237-42. (abstract)

GROUP VIII: Primary Human Kidney Cancer


- (1) Ito H, Yamaguchi K, Kotake T & Matsuzaki O (Dec. 1989) *Development of a serum-free medium and primary culture of human renal cell carcinomas by serum-free culture.* Nippon Hinyokika Gakkai Zasshi 80(12)1741-8. (abstract)

GROUP IX: Primary Human Gastric Cancer

- (1) Yanagihara K, Kamada N Tsumuraya M & Amano F (May 1993) *Establishment and characterization of a human gastric scirrhous carcinoma cell line in serum-free chemically defined medium*. In J Cancer 54(2)200-207. (abstract)

GROUP X: Primary Human Bladder Cancer

- (1) Messing EM, Fahey JL, deKernion JB, Bhuta SM & Bubbers JE (Jun 1982) *Serum-free medium for the in vitro growth of normal and malignant urinary bladder epithelial cells*. Cancer Res 42(6)2392-2397. (abstract)
- (2) Ito H, Yamaguchi K, Kotake T & Matsuzaki O (Dec 1989) *Primary culture of human bladder carcinomas and establishment of human bladder carcinoma cell line by serum-free culture*. Nippon Hinyokika Gakkai Zasshi 80:1749-1754. (abstract)



PTO/SB/21(08-03)

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/852,547
	Filing Date	May 10, 2001
	First Named Inventor	David A. Sirbasku
	Art Unit	1642
	Examiner Name	Karen A. Canella
Total Number of Pages in This Submission	Attorney Docket Number	1944-00800

ENCLOSURES (check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply (31 p.) <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input checked="" type="checkbox"/> Extension of Time Request (1 p.) <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (Supplemental) (2 p.) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): • Copy of article "Hormone-Receptor Interactions" (5 p.) • Form PTO-1449 (3 p.) (w/copies of cited references) • Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm Or Individual Name	Carol G. Mintz, PTO Reg. No. 38,561
Signature	<i>Carol G. Mintz</i>
Date	September 23, 2004

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment , Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or Printed Name	Frances Hampton		
Signature	<i>Frances Hampton</i>	Date	September 23, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and selection option 2



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

**FEE TRANSMITTAL
For FY 2004**

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** **\$655.00****Complete if Known**

Application Number	09/852,547
Filing Date	May 10, 2001
First Named Inventor	David A. Sirbasku
Examiner Name	Karen A. Canella
Art Unit	1642
Attorney Docket Number	1944-00800

METHOD OF PAYMENT (Check all that apply)☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:
Deposit Account Number: 03-2769
Deposit Account Name: Conley Rose, P.C.

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below
☒ Charge any additional fee(s) during the pendency of this application
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account
☒ Credit any overpayments**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 770	2001 385	Utility filing fee	\$
1002 340	2002 170	Design filing fee	\$
1003 530	2003 265	Plant filing fee	\$
1004 770	2004 385	Reissue filing fee	\$
1005 160	2005 80	Provisional filing fee	\$

SUBTOTAL (1) \$**2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

	Total Claims	Extra Claims	Fee from below	Fee Paid
	41	65 = 0 x	18.00 = \$	
Independent Claims	16	44 = 0 x	86.00 = \$	
Multiple Dependent			290.00 = \$	\$ 00.00

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 86	2201 43	Independent Claims in excess of 3
1203 290	2203 145	Multiple dependent claim, if not paid
1204 86	2204 43	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) \$0.00

** or number previously paid, if greater; For Reissues, see above

SUBMITTED BY**Complete (if applicable)**

Name (Print/Type)	Carol G. Mintz	Registration No. (Attorney/Agent)	38,561	Telephone	(713) 238-8000
Signature				Date	September 23, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-0PTO-9199 (1-800-786-9199) and select option 2.